In Brief: Endo Buys Somar; Neptune, Enzymotec Settle Dispute; FDA Prohibits Omega-3 Nutrient Claims
This article was originally published in The Tan Sheet
Executive Summary
Endo buys Somar; Neptune, Enzymotec settle patent infringement; FDA prohibits omega-3 nutrient claims; “Sell through” for herbals ends in U.K.; C&D licenses Nutrition 21’s chromium picolinate; Arizona DXM bill and Iowa Select Herbs drug claims.
You may also be interested in...
Pfizer Licenses Nutrition 21’s Chromax In Patent Claim Settlement
The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.